COYA · Coya Therapeutics Inc
United States · RS rating 14 · As of 2026-11-03
| Price | 3.11 USD |
|---|---|
| 1-day change | -3.7% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 9 / 19 / 21 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 27 / 8 / 37 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +12.5% |
| Sales growth Q/Q | +11.1% |
| Distance from 52-week high | +52.2% |
| Market cap (USD) | $101.8M |